Loading...
•
Jun 30, 2021
CareDx Q2 2021 Earnings Report
Reported a revenue growth of 77% for the second quarter of 2021.
Key Takeaways
CareDx reported a strong second quarter in 2021, with a 77% increase in revenue compared to the same period last year. The company's total revenue reached $74.2 million, driven by growth in testing services and product revenue. They increased full year revenue guidance to $280 million to $290 million.
Total revenue reached $74.2 million, a 77% increase year-over-year.
Approximately 37,400 AlloSure and AlloMap patient results were provided, including 6,600 AlloSure Heart patient results.
Over 65 U.S.-based transplant centers have adopted an AlloSure Kidney testing protocol.
TX Connect manages over 29,000 transplant referrals to over 50 transplant centers from more than 800 dialysis centers and community nephrology practices.
Revenue by Segment
Forward Guidance
CareDx now expects revenue to be in the range of $280 million to $290 million for the full year 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...